CN1193756C - 用作诊断和治疗靶点的sgk2和sgk3 - Google Patents
用作诊断和治疗靶点的sgk2和sgk3 Download PDFInfo
- Publication number
- CN1193756C CN1193756C CNB018163351A CN01816335A CN1193756C CN 1193756 C CN1193756 C CN 1193756C CN B018163351 A CNB018163351 A CN B018163351A CN 01816335 A CN01816335 A CN 01816335A CN 1193756 C CN1193756 C CN 1193756C
- Authority
- CN
- China
- Prior art keywords
- sgk3
- purposes
- sgk2
- active component
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Eye Examination Apparatus (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Radar Systems Or Details Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10042137A DE10042137A1 (de) | 2000-08-28 | 2000-08-28 | sgk2 und sgk3 als diagnostische und therapeutische Targets |
DE10042137.7 | 2000-08-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1466456A CN1466456A (zh) | 2004-01-07 |
CN1193756C true CN1193756C (zh) | 2005-03-23 |
Family
ID=7653998
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB018163351A Expired - Fee Related CN1193756C (zh) | 2000-08-28 | 2001-08-28 | 用作诊断和治疗靶点的sgk2和sgk3 |
Country Status (18)
Country | Link |
---|---|
US (1) | US20040038882A1 (el) |
EP (1) | EP1313476B1 (el) |
JP (1) | JP2004507493A (el) |
CN (1) | CN1193756C (el) |
AT (1) | ATE343386T1 (el) |
AU (2) | AU8403801A (el) |
CA (1) | CA2419472A1 (el) |
CY (1) | CY1105942T1 (el) |
DE (2) | DE10042137A1 (el) |
DK (1) | DK1313476T3 (el) |
ES (1) | ES2275713T3 (el) |
HK (1) | HK1061801A1 (el) |
HU (1) | HUP0302938A3 (el) |
MX (1) | MXPA03001739A (el) |
PL (1) | PL359714A1 (el) |
PT (1) | PT1313476E (el) |
RU (1) | RU2310471C2 (el) |
WO (1) | WO2002017893A2 (el) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10346913A1 (de) * | 2003-10-09 | 2005-05-04 | Merck Patent Gmbh | Acylhydrazonderivate |
WO2005094829A1 (en) * | 2004-03-11 | 2005-10-13 | Merck Patent Gmbh | Methods for modulating glutamate receptors for treating neuropsychiatric disorders comprising the use of modulators of serum and glucocorticoid inducible kinases |
WO2005118832A2 (en) * | 2004-06-01 | 2005-12-15 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase-like protein (sgkl) |
DE102007002717A1 (de) | 2007-01-18 | 2008-07-24 | Merck Patent Gmbh | Heterocyclische Indazolderivate |
DE102007022565A1 (de) | 2007-05-14 | 2008-11-20 | Merck Patent Gmbh | Heterocyclische Indazolderivate |
DE102008029072A1 (de) * | 2008-06-10 | 2009-12-17 | Lang, Florian, Prof. Dr.med. | Sgk3 als therapeutisches und diagnostisches Target für Alterserkrankungen |
DE102008038222A1 (de) | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | Indazol-5-carbonsäurehydrazid-derivate |
DE102008038220A1 (de) | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | Oxadiazolderivate |
DE102008038221A1 (de) | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | 7-Azaindolderivate |
EP2177510A1 (en) | 2008-10-17 | 2010-04-21 | Universität des Saarlandes | Allosteric protein kinase modulators |
DE102008059133A1 (de) | 2008-11-26 | 2010-05-27 | Merck Patent Gmbh | Difluorphenyl-diacylhydrazid-derivate |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5242397A (en) * | 1989-06-20 | 1993-09-07 | Cedars-Sinai Medical Center | Catheter device and method of use for intramural delivery of protein kinase C and tyrosine protein kinase inhibitors to prevent restenosis after balloon angioplasty |
US5385915A (en) * | 1990-05-16 | 1995-01-31 | The Rockefeller University | Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation |
US5137912A (en) * | 1991-01-28 | 1992-08-11 | National Science Council Of Republic Of China | Chelerythrine inhibits platelet aggregation--a potential anti-aggregation drug |
US5243397A (en) * | 1992-11-25 | 1993-09-07 | Elop-Electrooptics Industries Ltd. | Distance measuring system |
GB9325395D0 (en) * | 1993-12-11 | 1994-02-16 | Ciba Geigy Ag | Compositions |
US7625697B2 (en) * | 1994-06-17 | 2009-12-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for constructing subarrays and subarrays made thereby |
US6083920A (en) * | 1995-12-21 | 2000-07-04 | Ayurcore, Inc. | Compositions for modulating intracellular inositol trisphosphate concentration |
DE19708173A1 (de) * | 1997-02-28 | 1998-09-03 | Dade Behring Marburg Gmbh | Zellvolumenregulierte humane Kinase h-sgk |
EP0887081B1 (en) * | 1997-06-27 | 2003-04-23 | Smithkline Beecham Corporation | Human serum glucocorticoid regulated kinase, a target for chronic renal disease and diabetic nephropathy |
EP0889127A1 (en) * | 1997-07-01 | 1999-01-07 | Smithkline Beecham Corporation | Serine/threonine protein kinase (H-SGK2) |
CO4940430A1 (es) * | 1997-07-07 | 2000-07-24 | Novartis Ag | Compuestos policiclicos que contienen estaurosporina hidrogenada con propiedades farmacologicas convenientes y un efecto inhibidor sobre el crecimiento de las celulas tumorales |
JP4431798B2 (ja) * | 1997-10-08 | 2010-03-17 | 昇 金子 | 尿中のアネキシンvの分析方法及びその利用 |
US6162613A (en) * | 1998-02-18 | 2000-12-19 | Vertex Pharmaceuticals, Inc. | Methods for designing inhibitors of serine/threonine-kinases and tyrosine kinases |
WO1999061039A2 (en) * | 1998-05-22 | 1999-12-02 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Novel composition for modulating ischemic cell death |
DE19917990A1 (de) * | 1999-04-20 | 2000-11-02 | Florian Lang | Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk |
ATE441107T1 (de) * | 2002-03-01 | 2009-09-15 | Siemens Healthcare Diagnostics | Assays zur überwachung von krebspatienten auf grundlage der spiegel des analyten für die extrazelluläre domäne (ecd) des epidermalen wachstumsfaktor-rezeptors (egfr), allein oder in kombination mit anderen analyten, in proben von kírperflüssigkeiten |
-
2000
- 2000-08-28 DE DE10042137A patent/DE10042137A1/de not_active Withdrawn
-
2001
- 2001-08-28 PL PL01359714A patent/PL359714A1/xx not_active Application Discontinuation
- 2001-08-28 CA CA002419472A patent/CA2419472A1/en not_active Abandoned
- 2001-08-28 DK DK01962975T patent/DK1313476T3/da active
- 2001-08-28 HU HU0302938A patent/HUP0302938A3/hu unknown
- 2001-08-28 CN CNB018163351A patent/CN1193756C/zh not_active Expired - Fee Related
- 2001-08-28 RU RU2003107920/15A patent/RU2310471C2/ru not_active IP Right Cessation
- 2001-08-28 AT AT01962975T patent/ATE343386T1/de not_active IP Right Cessation
- 2001-08-28 MX MXPA03001739A patent/MXPA03001739A/es active IP Right Grant
- 2001-08-28 EP EP01962975A patent/EP1313476B1/de not_active Expired - Lifetime
- 2001-08-28 WO PCT/EP2001/009890 patent/WO2002017893A2/de active IP Right Grant
- 2001-08-28 DE DE50111328T patent/DE50111328D1/de not_active Expired - Fee Related
- 2001-08-28 AU AU8403801A patent/AU8403801A/xx active Pending
- 2001-08-28 PT PT01962975T patent/PT1313476E/pt unknown
- 2001-08-28 ES ES01962975T patent/ES2275713T3/es not_active Expired - Lifetime
- 2001-08-28 JP JP2002522867A patent/JP2004507493A/ja not_active Withdrawn
- 2001-08-28 AU AU2001284038A patent/AU2001284038B2/en not_active Ceased
- 2001-08-28 US US10/362,930 patent/US20040038882A1/en not_active Abandoned
-
2004
- 2004-07-05 HK HK04104810A patent/HK1061801A1/xx not_active IP Right Cessation
-
2007
- 2007-01-22 CY CY20071100078T patent/CY1105942T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
MXPA03001739A (es) | 2004-09-27 |
JP2004507493A (ja) | 2004-03-11 |
EP1313476A2 (de) | 2003-05-28 |
WO2002017893A3 (de) | 2003-01-23 |
CN1466456A (zh) | 2004-01-07 |
CY1105942T1 (el) | 2011-04-06 |
PL359714A1 (en) | 2004-09-06 |
HK1061801A1 (en) | 2004-10-08 |
AU2001284038B2 (en) | 2007-03-22 |
ES2275713T3 (es) | 2007-06-16 |
DK1313476T3 (da) | 2007-02-26 |
HUP0302938A3 (en) | 2009-03-02 |
WO2002017893A2 (de) | 2002-03-07 |
US20040038882A1 (en) | 2004-02-26 |
CA2419472A1 (en) | 2003-02-26 |
DE10042137A1 (de) | 2002-03-14 |
AU8403801A (en) | 2002-03-13 |
DE50111328D1 (de) | 2006-12-07 |
HUP0302938A2 (hu) | 2003-12-29 |
RU2310471C2 (ru) | 2007-11-20 |
ATE343386T1 (de) | 2006-11-15 |
EP1313476B1 (de) | 2006-10-25 |
PT1313476E (pt) | 2007-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Adachi et al. | c-Myc is necessary for DNA damage-induced apoptosis in the G2 phase of the cell cycle | |
Erecinska et al. | Energy metabolism in mammalian brain during development | |
Saxena et al. | Leptin as a novel profibrogenic cytokine in hepatic stellate cells: mitogenesis and inhibition of apoptosis mediated by extracellular regulated kinase (Erk) and Akt phosphorylation | |
Krawiec et al. | AMP-activated protein kinase agonists increase mRNA content of the muscle-specific ubiquitin ligases MAFbx and MuRF1 in C2C12 cells | |
CN1193756C (zh) | 用作诊断和治疗靶点的sgk2和sgk3 | |
Schaaf et al. | Downregulation of BDNF mRNA and protein in the rat hippocampus by corticosterone | |
Briscoe et al. | Kinase‐negative mutants of JAK1 can sustain interferon‐gamma‐inducible gene expression but not an antiviral state. | |
Nystrom et al. | Sepsis and AMPK activation by AICAR differentially regulate FoxO-1,-3 and-4 mRNA in striated muscle | |
Stockand et al. | Mechanism of activation by cGMP-dependent protein kinase of large Ca (2+)-activated K+ channels in mesangial cells | |
NZ540427A (en) | Methods for selectively inhibiting janus tyrosine kinase 3 (Jak3) | |
Gaines et al. | Mouse neutrophils lacking lamin B-receptor expression exhibit aberrant development and lack critical functional responses | |
Verónica Donoso et al. | Pharmacological dissection of the cellular mechanisms associated to the spontaneous and the mechanically stimulated ATP release by mesentery endothelial cells: roles of thrombin and TRPV | |
Uyama et al. | Carbenoxolone inhibits DNA synthesis and collagen gene expression in rat hepatic stellate cells in culture | |
Banzet et al. | Contraction‐induced interleukin‐6 transcription in rat slow‐type muscle is partly dependent on calcineurin activation | |
Sapkota et al. | GHRH Neurons from the Ventromedial Hypothalamic Nucleus Provide Dynamic and Sex-Specific Input to the Brain Glucose-Regulatory Network | |
EP1523571B1 (de) | Sgk und nedd als diagnostische und therapeutische targets | |
EP1613766A1 (de) | Sgk1 als diagnostisches und therapeutisches target | |
Rexhepaj et al. | PI3 kinase and PDK1 in the regulation of the electrogenic intestinal dipeptide transport | |
Carson-Walter et al. | Post-transcriptional silencing of RET occurs, but is not required, during raf-1 mediated differentiation of medullary thyroid carcinoma cells | |
Ballard et al. | Signal transduction mechanism for the stimulation of the sarcolemmal Na+− Ca 2+ exchanger by insulin | |
DE10149393A1 (de) | sgk1 als diagnostisches und therapeutisches target | |
Buzas et al. | Ca2+/calmodulin‐dependent transcriptional activation of δ‐opioid receptor gene expression induced by membrane depolarization in NG108‐15 cells | |
Heyworth et al. | Naphthalenesulphonamides block neutrophil superoxide production by intact cells and in a cell-free system: is myosin light chain kinase responsible for these effects? | |
Won et al. | The differential molecular mechanisms underlying proenkephalin mRNA expression induced by forskolin and phorbol-12-myristic-13-acetate in primary cultured astrocytes | |
Ainsworth et al. | Intracellular signaling events in superoxide generation and adhesion of channel catfish, Ictalurus punctatus rafinesque, neutrophils to the extracellular matrix protein fibrinogen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1061801 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |